A William Blair analyst initiated coverage of EndoChoice, giving it an "outperform" rating, according to a Benzinga report.
Here are four notes:
1. The analyst believes that the company's Fuse endoscopy system, along with its single use products, will drive sustainable growth of 20 percent to 30 percent for the next few years.
2. Fuse endoscopy provides up to a 330 degree view of the colon, and a study found that the system allows doctors to detect 69 percent more adenomas than existing technology.
3. The analyst believes that Fuse could contribute nearly 80 percent of EndoChoice's revenue growth through 2018.
4. "EndoChoice is the only company to address the continuum of care in the $6 billion worldwide gastrointestinal market through its single-use products, Fuse endoscopy system and in-house pathology services," notes the William Blair report.